Professional Documents
Culture Documents
doi:10.1093/eurheartj/ehi204
ESC Guidelines
ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Jean-Jacques Blanc (France),
Andrzej Budaj (Poland), John Camm (UK), Veronica Dean (France), Jaap Deckers (The Netherlands),
Kenneth Dickstein (Norway), John Lekakis (Greece), Keith McGregor (France), Marco Metra (Italy),
o Morais (Portugal), Ady Osterspey (Germany), Juan Tamargo (Spain), Jose
Luis Zamorano (Spain)
Joa
hm (Germany), Alain Cohen-Solal
Document Reviewers, Marco Metra (CPG Review Coordinator) (Italy), Michael Bo
m (Sweden), Kenneth Dickstein (Norway), Gerasimos S. Filippatos
(France), Martin Cowie (UK), Ulf Dahlstro
(Greece), Edoardo Gronda (Italy), Richard Hobbs (UK), John K. Kjekshus (Norway), John McMurray (UK),
n (Sweden), Gianfranco Sinagra (Italy), Juan Tamargo (Spain), Michal Tendera (Poland),
Lars Ryde
Dirk van Veldhuisen (The Netherlands), Faiez Zannad (France)
Online publish-ahead-of-print 18 May 2005
Table of Contents
Preamble . . . . . . . . . . . . . . . . . . . . . . . . 1116
Diagnosis of chronic heart failure . . . . . . . . . . 1116
Introduction . . . . . . . . . . . . . . . . . . . . . 1116
Methodology . . . . . . . . . . . . . . . . . . . .
Epidemiology . . . . . . . . . . . . . . . . . . . . .
Descriptive terms in heart failure . . . . . . . . .
Acute vs. chronic heart failure . . . . . . . . .
Systolic vs. diastolic heart failure . . . . . . .
Other descriptive terms in heart failure . . . .
Denition of chronic heart failure . . . . . . .
Aspects of the pathophysiology of the symptoms
of heart failure relevant to diagnosis . . . . . . .
Possible methods for the diagnosis of heart
failure in clinical practice . . . . . . . . . . . . .
1116
1117
1117
1117
1118
1118
1118
1119
1119
& The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
1116
1119
1120
1120
1120
1120
1120
1120
1121
1122
1122
1122
1122
1122
1122
1122
1122
1122
1123
1123
1124
1124
1125
1125
1125
1126
1126
1127
1128
1128
1128
1129
1130
1130
1131
1131
1131
1131
1131
1131
1131
1132
1132
1132
1132
1133
1134
1134
1135
1135
1135
1135
1135
1135
Ventricular arrhythmias . . . . . . . . . . . . .
Atrial brillation . . . . . . . . . . . . . . . . .
Symptomatic systolic left ventricular dysfunction
and concomitant angina or hypertension . . . .
Care and follow-up . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . .
1136
1136
1136
1136
1136
Preamble
Guidelines and Expert Consensus Documents aim to
present all the relevant evidence on a particular issue in
order to help physicians to weigh the benets and risks
of a particular diagnostic or therapeutic procedure. They
should be helpful in everyday clinical decision-making.
A great number of Guidelines and Expert Consensus
Documents have been issued in recent years by the
European Society of Cardiology (ESC) and by different
organizations and other related societies. This profusion
can put at stake the authority and validity of guidelines,
which can only be guaranteed if they have been developed by an unquestionable decision-making process.
This is one of the reasons why the ESC and others have
issued recommendations for formulating and issuing
Guidelines and Expert Consensus Documents.
In spite of the fact that standards for issuing good
quality Guidelines and Expert Consensus Documents are
well dened, recent surveys of Guidelines and Expert
Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast
majority of cases. It is therefore of great importance
that guidelines and recommendations are presented in
formats that are easily interpreted. Subsequently, their
implementation programmes must also be well conducted. Attempts have been made to determine
whether guidelines improve the quality of clinical practice and the utilization of health resources.
The ESC Committee for Practice Guidelines (CPG)
supervises and coordinates the preparation of new
Guidelines and Expert Consensus Documents produced
by Task Forces, expert groups, or consensus panels. The
chosen experts in these writing panels are asked to
provide disclosure statements of all relationships they
may have which might be perceived as real or potential
conicts of interest. These disclosure forms are kept on
le at the European Heart House, headquarters of the
ESC. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus
Documents or statements.
The Task Force has classied and ranked the usefulness
or efcacy of the recommended procedure and/or treatments and the Level of Evidence as indicated in the
tables on page 3.
ESC Guidelines
ESC Guidelines
Epidemiology
.
Classes of recommendations
Class I
Class II
Class IIa
Class IIb
Class III
Levels of evidence
Level of Evidence A
Level of Evidence B
Level of Evidence C
1117
1118
ESC Guidelines
The present document will concentrate on the syndrome of CHF and leave out aspects on AHF.13 Thus,
heart failure, if not stated otherwise, is referring to the
chronic state.
Figure 1
Relationship between cardiac dysfunction, heart failure, and heart failure rendered asymptomatic.
ESC Guidelines
1119
Figure 2
1120
Table 2
failure
ESC Guidelines
Electrocardiographic changes are common in patients suspected of having heart failure whether or not the diagnosis
proves to be correct. An abnormal ECG, therefore, has
little predictive value for the presence of heart failure.
On the other hand, if the ECG is completely normal,
heart failure, especially due LV systolic dysfunction, is
unlikely. The presence of pathological Q-waves may
suggest myocardial infarction as the cause of cardiac
dysfunction. A QRS width .120 ms suggests that cardiac
dyssynchrony may be present and a target for treatment.
.
.
Echocardiography
.
.
Electrocardiogram
Natriuretic peptides
ESC Guidelines
Transoesophageal echocardiography is not recommended routinely and can only be advocated in patients
who have an inadequate echo window, in complicated
valvular patients, and in patients with suspected dysfunction of mechanical mitral valve prosthesis or when it is
mandatory to identify or exclude a thrombus in the
atrial appendage.
Repeated echocardiography can be recommended in
the follow-up of patients with heart failure only when
there is an important change in the clinical status
suggesting signicant improvement or deterioration in
cardiac function.
Figure 3 The three lling patterns impaired relaxation, pseudonormalised lling, and restrictive lling represent mild, moderate, and severe
diastolic dysfunction, respectively.37
1121
1122
Pulmonary function
.
ESC Guidelines
Exercise testing
.
Invasive investigation
.
Cardiac catheterization
Coronary angiography should be considered in patients
with acute or acutely decompensated CHF and in patients
with severe heart failure (shock or acute pulmonary
oedema) who are not responding to initial treatment.
Coronary angiography should also be considered in
patients with angina pectoris or any other evidence of
myocardial ischaemia if they are not responding to appropriate anti-ischaemic treatment. Revascularization has
not been shown to alter prognosis in heart failure in
clinical trials and therefore, in the absence of angina
pectoris unresponsive to medical therapy, coronary
arteriography is not indicated. Coronary angiography
is also indicated in patients with refractory heart
failure of unknown aetiology and in patients with
evidence of severe mitral regurgitation or aortic valve
disease.
Monitoring of haemodynamic variables by means of a
pulmonary arterial catheter is indicated in patients who
are hospitalized for cardiogenic shock or to direct treatment of patients with CHF not responding promptly to
initial and appropriate treatment. Routine right heart
catheterization should not be used to tailor chronic
therapy.
Prognostication
.
Tests of neuroendocrine activation are not recommended for diagnostic or prognostic purposes in
individual patients.
ESC Guidelines
1123
Table 3 Assessments to be performed routinely to establish the presence and likely cause of heart failure
Assessments
Appropriate symptoms
Appropriate signs
Cardiac dysfunction on Imaging
(usually echocardiography)
Response of symptoms or signs
to therapy
ECG
Chest X-ray
Suggests alternative
or additional diagnosis
Supports
Opposes
(If absent)
(If absent)
(If absent)
(If absent)
If pulmonary
congestion or
cardiomegaly
(If Normal)
(If normal)
(If elevated)
(If normal)
Pulmonary disease
Anaemia/secondary
polycythaemia
Renal or hepatic
disease/diabetes
Can be normal in
treated patients
Tests
Suggests alternative or
additional diagnosis
Supports
Opposes
Exercise test
Pulmonary function tests
Thyroid function tests
Invasive investigation
and angiography
Cardiac output
(If impaired)
(If normal)
Pulmonary disease
Thyroid disease
Coronary artery
disease, ischaemia
(If depressed at rest)
Table 4 Additional tests to be considered to support the diagnosis or to suggest alternative diagnoses
1124
ESC Guidelines
NYHA functional
Class IIIIV 123,124,144
Low body-mass index148
Diabetes143
Ventilatory rhythm
and rate
disturbances151,152
Resuscitated
sudden death 110
Race126
Clinical
Dietary measures
Sodium. Controlling the amount of salt in the diet is a
problem, that is, more important in advanced than in
mild heart failure.
Weight monitoring
Patients are advised to weigh on a regular basis to
monitor weight gain (preferably as part of a regular
daily routine, for instance after morning toilet) and,
in case of a sudden unexpected weight gain of .2 kg in
3 days, to alert a health care provider or adjust their
diuretic dose accordingly (e.g. to increase the dose if a
sustained increase in weight is noted).
Electrophysiologic
CHF chronic heart failure; BP blood pressure; NYHA New York Heart Association; VE ventilation volume per min; VCO2 ventilation of CO2; BNP brain natriuretic peptide; LVEF left ventricular ejection fraction.
Strong.
(Class of recommendation I, level of evidence C for nonpharmacological management unless stated otherwise)
Non-pharmacological management
Broad QRS95,127
Central haemodynamic
Blood
Establish that the patient has heart failure (in accordance with
the denition presented on page 1122, diagnosis section)
Ascertain presenting features: pulmonary oedema, exertional
breathlessness, fatigue, peripheral oedema
Assess severity of symptoms
Determine aetiology of heart failure
Identify precipitating and exacerbating factors
Identify concomitant diseases relevant to heart failure and its
management
Estimate prognosis based on page 1124, Table 6.
Assess complicating factors (e.g. renal dysfunction, arthritis)
Counsel patient and relatives
Choose appropriate management
Monitor progress and manage accordingly
Functional/exertional
ESC Guidelines
Drug counselling
Self-management (when practical) of the dose of the
diuretic, based on changes in symptoms and weight
(uid balance), should be encouraged. Within pre-specied and individualized limits, patients are able to
adjust their diuretics.
Drugs to avoid or beware
The following drugs should be used with caution when coprescribed with any form of heart failure treatment or
avoided:
(i) Non-steroidal anti-inammatory drugs (NSAIDS) and
coxibs
(ii) Class I anti-arrhythmic agents (page 1131)
(iii) Calcium antagonists (verapamil, diltiazem, and
short-acting dihydropyridine derivatives (page 1126)
(iv) Tricyclic anti-depressants
(v) Corticosteroids
(vi) Lithium
Pharmacological therapy
Angiotensin-converting enzyme inhibitors
.
Travelling
High altitudes or very hot or humid places should be discouraged. In general, short air ights are preferable to
long journeys by other means of transport.
Sexual activity
It is not possible to dictate guidelines about sexual
activity counselling. Recommendations are given to reassure the not severely compromised, but frightened
patient, to reassure the partner who is often even more
frightened, and perhaps refer the couple for specialist
counselling. Little is known about the effects of treatments for heart failure on sexual function.
Advice on immunizations
There is no documented evidence of the effects of immunization in patients with heart failure. Immunization for
inuenza is widely used.
Asymptomatic patients with a documented left ventricular systolic dysfunction should be treated with an
ACE-inhibitor to delay or prevent the development of
heart failure. ACE-inhibitors also reduce the risk of
Obesity
Treatment of CHF should include weight reduction in
obese patients.
1125
1126
Diuretics
Loop diuretics, thiazides, and metolazone
.
Potassium-sparing diuretics
.
Table 8 Doses of ACE-inhibitors shown to be effective in large, controlled trials of heart failure, or left ventricular dysfunction
Studies of mortality
Drug
Target dose
Studies in CHF
CONSENSUS Trial Study Group, 198748
V-HeFT II, 1991161
The SOLVD Investigators, 1991162
ATLAS, 1999163
Enalapril
Enalapril
Enalapril
Lisinopril
20 mg b.i.d.
10 mg b.i.d.
10 mg b.i.d.
High dose:
Low dose:
18.4 mg
15.0 mg
16.6 mg
32.535 mg daily
2.55 mg daily
Captopril
Ramipril
Trandolapril
50 mg t.i.d.
5 mg b.i.d.
4 mg daily
127 mg
(not available)
(not available)
ESC Guidelines
ESC Guidelines
1127
Initiating dose
Table 11 Diuretics
Initial diuretic treatment
Loop diuretics or thiazides. Always administered
in addition to an ACE-inhibitor
If GFR ,30 mL/min, do not use thiazides, except as
therapy prescribed synergistically with loop diuretics
Insufcient response:
Increase dose of diuretic
Combine loop diuretics and thiazides
With persistent uid retention: administer loop diuretics
twice daily
In severe heart failure add metolazone with frequent
measurement of creatinine and electrolytes
Potassium-sparing diuretics: triamterene, amiloride and
spironolactone
Use only if hypokalaemia persists after initiation of
therapy with ACE, inhibitors and diuretics
Start one-week low-dose administration; check serum
potassium and creatinine after 57 days and titrate
accordingly. Recheck every 57 days until potassium
values are stable
Maintenance
dose
antagonists due to hyperkalaemia and renal dysfunction, amiloride or triamterene may be used (Class of recommendation IIb, level of evidence C).
Potassium supplements are generally ineffective in this
situation (Class of recommendation III, level of evidence C).
The use of all potassium-sparing diuretics should be
monitored by repeated measurements of serum creatinine and potassium. A practical approach is to measure
serum creatinine and potassium every 57 days after
initiation of treatment until the values are stable. Thereafter, measurements can be made every 36
months.
Beta-adrenoceptor antagonists
.
Initiation of therapy
The initial dose should be small and increased slowly and
progressively to the target dose used in the large clinical
trials. Up-titration should be adapted to individual
responses.
1128
ESC Guidelines
Maximum recommended
daily dose (mg)
2040
250500
0.51.0
510
510
100200
2.5
25
10
5075
2.5
2.5
10
2.5
ACEI
2.5
25
12.525
2ACEI
5
50
50
ACEI
20
100
50
Hypokalaemia, hypomagnesaemia,
hyponatraemia
Hyperuricaemia, glucose intolerance
Acidbase disturbance
Hypokalaemia, hypomagnesaemia,
hyponatraemia
Hyperuricaemia, glucose intolerance
Acidbase disturbance
2ACEI
40
200
100200
Hyperkalaemia, rash
Hyperkalaemia
Hyperkalaemia, gynaecomastia
Cardiac glycosides
.
ESC Guidelines
1129
Table 14 Initiating dose, target dose, and titration scheme of beta-blocking agents as used in recent large, controlled trials
Beta-blocker
164
Bisoprolol
Metoprolol succinate CR165
Carvedilol54
Nebivolol58
Increments (mg/day)
Titration period
1.25
12.5/25
3.125
1.25
10
200
50
10
Weeksmonth
Weeksmonth
Weeksmonth
Weeksmonth
Digoxin
The usual daily dose of oral digoxin is 0.1250.25 mg if
serum creatinine is in the normal range (in the elderly
0.06250.125 mg, occasionally 0.25 mg).
Hydralazine-isosorbide dinitrate
.
g. Asthma bronchiale
h. Severe bronchial disease
i. Symptomatic bradycardia or hypotension
1130
ESC Guidelines
Nitrates
.
Anti-thrombotic agents
.
There is no evidence to support the use of alphaadrenergic blocking drugs in heart failure (Class of recommendation III, level of evidence B).75
Calcium antagonists
.
ESC Guidelines
1131
Revascularization
.
Anti-arrhythmics
Anti-arrhythmic drugs other than beta-blockers are
generally not indicated in patients with CHF. In patients
with atrial brillation (rarely utter), non-sustained, or
sustained ventricular tachycardia treatment with antiarrhythmic agents may be indicated.
Class I anti-arrhythmics
.
Class II anti-arrhythmics
.
LV aneurysmectomy
.
Oxygen therapy
.
Mitral valve surgery in patients with severe left ventricular systolic dysfunction and severe mitral valve insufciency due to ventricular insufency may lead to
symptomatic improvement in selected heart failure
patients (Class of recommendation IIb, level of evidence C). This is also true for secondary mitral insufciency due to left ventricular dilatation.
Cardiomyoplasty
.
1132
Pacemakers
.
Implantation of an implantable cardioverter debrillators (ICD) in combination with bi-ventricular pacing can
be considered in patients who remain symptomatic
with severe heart failure NYHA class IIIIV with
LVEF 35% and QRS duration 120 ms to improve mortality or morbidity (Class of recommendation IIa, level
of evidence B).93
ICD therapy is recommended to improve survival in
patients who have survived cardiac arrest or who have
sustained ventricular tachycardia, which is either
poorly tolerated or associated with reduced systolic
left ventricular function (Class of recommendation I,
level of evidence A).95
ICD implantation is reasonable in selected patients with
LVEF , 3035%, not within 40 days of a myocardial
infarction, on optimal background therapy including
ACE-inhibitor, ARB, beta-blocker, and an aldosterone
antagonist, where appropriate, to reduce sudden
death (Class of recommendation I, level of evidence
A).90,96,97
In patients with documented sustained ventricular tachycardia or ventricular brillation, the ICD is highly effective in treating recurrences of these arrhythmias, either
by anti-tachycardia pacing or cardioversion/debrillation, thereby reducing morbidity and the need for
rehospitalization. The selection criteria, the limited
follow-up and increased morbidity associated with ICD-
Patients who should be considered for heart transplantation are those with severe symptoms of heart failure
with no alternative form of treatment and with a poor
prognosis. The introduction of new treatments has probably modied the prognostic signicance of the variables
traditionally used to identify heart transplant candidates
i.e. VO2 max (see prognostication page 1122). The
patient must be willing and capable to undergo intensive
medical treatment, and be emotionally stable so as to
withstand the many uncertainties likely to occur both
ESC Guidelines
ESC Guidelines
.
.
.
.
Ultraltration
.
1133
1134
Table 18
ESC Guidelines
Angiotensin
receptor
blocker
Diuretic
Beta-blocker
Aldosterone
antagonists
Cardiac glycosides
Indicated
If ACE intolerant
Not indicated
Post MI
Recent MI
Indicated
Indicated with
or without
ACE-inhibitor
Indicated if
uid retention
Indicated
Recent MI
With atrial
brillation
(a) when atrial
brillation
(b) when improved
from more
severe HF in
sinus rhythm
Worsening HF
(NYHA IIIIV)
Indicated
Indicated
Indicated
Indicated
Indicated,
combination
of diuretics
Indicated,
combination
of diuretics
Indicated (under
specialist care)
End-stage HF
(NYHA IV)
Indicated with
or without
ACE-inhibitor
Indicated with
or without
ACE-inhibitor
Indicated (under
specialist care)
Indicated
Indicated
Asymptomatic LV
dysfunction
Symptomatic
HF (NYHA II)
Figure 4 Pharmacological therapy of symptomatic CHF that is equally systolic left ventricular dysfunction. The algorithm should primarily be viewed as
an example of how decisions on therapy can be made depending on the progression of heart failure severity. A patient in NYHA Class II can be followed
with proposals of decision-making steps. Individual adjustments must be taken into consideration.
ESC Guidelines
Cardiac
.
.
.
.
.
.
Atrial brillation
Other supraventricular or ventricular arrhythmias
Bradycardia
Myocardial ischaemia (frequently symptomless), including
myocardial infarction
Appearance or worsening of mitral or tricuspid
regurgitation
Excessive preload reduction (e.g. due to diuretics
ACE-inhibitors/nitrates)
Diuretic therapy
In the elderly, thiazides are often ineffective because of
reduced glomerular ltration rate. In elderly patients,
hyperkalaemia is more frequently seen with a combination of aldosterone antagonsist and ACE-inhibitors or
NSAIDs and coxibs.
Beta-blockers
Beta-blocking agents are surprisingly well tolerated in
the elderly if patients with such contraindications as
sick sinus node, AV-block and obstructive lung disease
are excluded. Beta-blockade should not be withheld
because of increasing age alone.
Cardiac glycosides
Elderly patients may be more susceptible to adverse
effects of digoxin. Initially, low dosages are recommended in patients with elevated serum creatinine.
Vasodilator agents
Venodilating drugs, such as nitrates and the arterial
dilator hydralazine and the combination of these drugs,
should be administered carefully because of the risk of
hypotension.
1135
1136
ESC Guidelines
Arrhythmias
.
Ventricular arrhythmias
.
Atrial brillation
If hypertension is present
.
.
.
References
1. The Task Force on Heart Failure of the European Society of
Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart
J 1995;16:741751.
2. The Task Force of the Working Group on Heart Failure of the
European Society of Cardiology. The treatment of heart failure.
Eur Heart J 1997;18:736753.
3. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment
of chronic heart failure. Eur Heart J 2001;22:15271560.
4. How to diagnose diastolic heart failure. European Study Group on
Diastolic Heart Failure. Eur Heart J 1998;19:9901003.
5. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure
and left ventricular dysfunction in the general population. Eur Heart
J 1999;20:447455.
(1)
(2)
(3)
(4)
ESC Guidelines
1137
1138
51.
52.
53.
54.
55.
56.
57.
58.
59.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72. Khand AU, Rankin AC, Kaye GC et al. Systematic review of the management of atrial brillation in patients with heart failure. Eur Heart
J 2000;21:614632.
73. Khand AU, Rankin AC, Martin W et al. Digoxin or carvedilol for the
treatment of atrial brillation in patients with heart failure?
(Abstract). Heart 2000;83:30.
74. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med
2004;351:20492057.
75. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy
on mortality in chronic congestive heart failure. Results of a
Veterans Administration Cooperative Study. N Engl J Med 1986;
314:15471552.
76. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist
felodipine as supplementary vasodilator therapy in patients
with chronic heart failure treated with enalapril: V-HeFT III.
Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation
1997;96:856863.
77. Thackray S, Witte K, Clark AL et al. Clinical trials update: OPTIMECHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2:209212.
78. Follath F, Cleland JG, Just H et al. Efcacy and safety of intravenous
levosimendan compared with dobutamine in severe low-output
heart failure (the LIDO study): a randomised double-blind trial.
Lancet 2002;360:196202.
79. Cleland JG, Cowburn PJ, Falk RH. Should all patients with atrial
brillation receive warfarin? Evidence from randomized clinical
trials. Eur Heart J 1996;17:674681.
80. Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ 2002;324:7186.
81. Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in
Heart failure (WASH): a randomized trial comparing antithrombotic
strategies for patients with heart failure. Am Heart J 2004;
148:157164.
82. Teo KK, Yusuf S, Pfeffer M et al. Effects of long-term treatment with
angiotensin-converting-enzyme inhibitors in the presence or
absence of aspirin: a systematic review. Lancet 2002;360:
10371043.
83. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and
cumulative meta-analyses from the American College of Cardiology:
WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIOLipids and cardiac resynchronisation therapy in heart failure. Eur J
Heart Fail 2004;6:501508.
84. The Cardiac Arrhythmia Suppression Trial. Preliminary report: effect
of encainide and ecainide on mortality in a randomized trial of
arrhythmia suppression after myocardial infarction. New Engl J
Med 1989;321:406412.
85. Lo
pez-Sendo
n J, Swedberg K, McMurray J et al. Expert consensus
document on beta-adrenergic receptor blockers. Eur Heart J 2004;
25:13411362.
86. Steinbeck G, Andresen D, Bach P et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with betablocker therapy in patients with symptomatic, sustained ventricular
tachyarrhythmias. N Engl J Med 1992;327:987992.
87. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and
in congestive heart failure: meta-analysis of individual data from
6500 patients in randomised trials. Lancet 1997;350:14171424.
88. Levy S, Breithardt G, Campbell RW et al. Atrial brillation: current
knowledge and recommendations for management. Working Group
on Arrhythmias of the European Society of Cardiology. Eur Heart J
1998;19:12941320.
89. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with
congestive heart failure and asymptomatic ventricular arrhythmia.
N Engl J Med 1995;333:7782.
90. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable
cardioverter-debrillator for congestive heart failure. N Engl J
Med 2005;352:225237.
91. Linde C, Leclercq C, Rex S et al. Long-term benets of biventricular
pacing in congestive heart failure: results from the MUltisite
STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol
2002;40:111118.
92. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization
in chronic heart failure. N Engl J Med 2002;346:18451853.
60.
ESC Guidelines
ESC Guidelines
1139
1140
ESC Guidelines